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INTRODUCTION
Among the nineteen functionally distinct endocrine cell types that populate the gas-
trointestinal mucosa, some (e.g., the serotonin-producing enterochromaffin (EC)b cells,
and the somatostatin-producing D cells, etc.) are dispersed diffusely all along its length,
while others (e.g., the histamine-producing enterochromaffin-like (ECL) cells, the gastrin-
producing G cells, the secretin-producing S cells and the cholecystokinin-producing I
cells) have a much more restricted distribution and are confined to specific segments or
anatomic locations (Figure 1). Since the secretory products ofthese cells act as chemical
messengers to orchestrate the absorptive, secretory and propulsive functions of the gut,
both the distributional pattern and the numerical density of the various cell types is pre-
ordained by the physiologic needs pertinent to a given anatomic segment or site [1]. Thus
the oxyntic (acid-producing) portion of the human gastric mucosa contains at least six
ultrastructurally distinct endocrine cells types: the EC cells, the ECLcells, the D cells, the
D1 cells, the P and the X cells. The vast majority ofthese cells are dispersed randomly in
the middle- and lower-third ofthe mucosal thickness, and only occasional endocrine cells
are seen in the superflcial third of the oxyntic mucosa. Rare stray endocrine cells have
additionally also been described in association with nerve fibers and Schwann cells (neu-
roendocrine complexes) in the lamina propria [2, 3].
The entire endocrine cell population of the oxyntic mucosa can be visualized by
immunohistochemical stains for such markers of neuroendocrine differentiation as chro-
mogranin A, neuron specific enolase, synaptophysin and pancreatostatin, etc., and can be
dissected into its component cell types by their specific histochemical or immunohisto-
chemical profiles (Figure 2). Histochemically, while these cells are argyrophil in nature,
not all of them can be simultaneously identified by any one argyrophil stain. Thus, the
Grimelius stain identifies all oxyntic endocrine cells except the D cells that show argy-
rophilia only with the Hellerstrom-Hellman technique. The Sevier-Munger technique for
argyrophilia, on the other hand, selectively stains the ECL cells and a small subset ofthe
EC and D1 cells (Figure 2). However, since the relative proportion ofthe EC and D1 cells
stained by this technique is negligible, the Sevier-Munger stain is currently regarded as
more orless specific forECLcells in formalin-fixed, paraffin-embedded tissues processed
for light microscopy. However, since the Sevier-Munger stain is technically difficult and
somewhat capricious, most workers rely on the Grimelius stain for visualizing ECL cells,
realizing fully well that the number ofpositively stained cells is not an accurate depiction
of their numbers since this technique also stains other argyrophil cells in the oxyntic
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Figure 1. Schematic depiction of the anatomic
distribution and the secretory products of the
various endocrine cell types in the gastroin-
testinal mucosa. The extentofthe solid lines indi-
cates the presence of the various cell types in the
different segmentsofthegut, whilethewidthdepicts
their relative population densities. The interrupted
lines denote the presence ofrelatively fewer cells
of a given type in that location. (Adapted from
Larsson, L.I. Scand. J. Gastroent. 14(suppl 53):128,
1979).
Figure 2. Diagramatic depiction ofthe endocrine cells ofthe human oxyntic mucosa, and the
immunohistochemical and histochemical stains commonly employed for their identification
and visualization.
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Table 1. Endocrine cells ofthe human oxyntic mucosa.
Cell Secretory Relative Volume CG-A Grimelius S-M H-H M-F
type product (%) density* stain stain stain stain stain
ECL Histamine 30-50 30+9 + + +
Calbindin
D Somatostatin 10-30 22 + 4 + - - +
EC Serotonin 5-15 7 + 5 + + + - +
Dl Unknown 5-10 9 + 8 + + +
P Bombesin? 5-10 24 + 7 + (+)
X Endothelin-1 1-5 0.6 + 0.7 + +
CG-A, chromogranin-A; S-M, Sevier-Munger stain for argyrophilia; H-H, Hellerstrom-Hellman
stain for argyrophilia; M-F, Masson-Fontana stain for argentaffinity.
*, volume density figures representmean + SD and indicate % ofthe whole endocrine cell mass [66].
+, positive; (+), weakly positive; -, negative; ±, few cells positive.
mucosa as well [4]. The relative numbers, secretory product(s), histochemical, immuno-
histochemical and ultrastructural characteristics of various endocrine cells in the human
oxyntic mucosa are summarized in Table 1.
ENTEROCHROMAFFIN-LIKE (ECL) CELLS - THEIR CURRENT STATUS
In all vertebrate species studied so far, the ECL cells are normally confined to the
oxyntic mucosa of the stomach and constitute its dominant endocrine cell type [5].
Scattered randomly in the lower and intermediate thirds of the mucosal thickness, these
closed-type endocrine cells lie in close proximity to the parietal and chiefcells. Although
they lack apical processes that are characteristic of open-type endocrine cells, the ECL
cells show prominent neuronal-like cytoplasmic processes that extend to and terminate on
the surface ofneighboring parietal and chiefcells (Figure 3). ECL cells thus release their
secretory products locally (to modulate parietal cell function by a paracrine mode of
action) and into the capillary network around the glands (to exert their endocrine mode of
function). In humans, the ECL cells are essentially identified by their topographic distri-
bution, their ability to stain with the Grimelius and the Sevier-Munger stains for argy-
rophilia and the ultrastructural features of their neurosecretory granules. The ECL cell
granules are morphologically heterogeneous. Most numerous, and regarded as character-
istic ofECLcells, are the large (up to 300 nm-sized) membrane-bound vesicles that have
an eccentrically locatedirregular, coarsely texturedelectron dense argyrophil core (Figure4).
In addition there may also be a variably sized minority population ofsmall round granules
with ahomogeneous coarsely granularcore surroundedby athin haloboundedby adelicate,
wavy limiting membrane. While some ECL cells contain both types of granules, others
may show only the small granules in their cytoplasm [6].
The ECLcells have receptors for a number ofregulatory substances and other chemical
mediators (e.g., gastrin, somatostatin and histamine, etc.) on their surface, and although a
variety of products including calbindin, a calcium-binding protein, the alpha subunit of
HCG, transforming growth factor-alpha (TGF-a), etc., have been localized in their cyto-
plasm, histamine has emerged as the most physiologically relevant secretory product of
the ECL cells [5, 7-10]. Whereas it was originally thought that gastrin directly stimulated
the parietal cells to secrete acid, this action is now believed to be mainly histamine-mediated;
the actual sequence ofevents is that gastrin stimulates the ECLcells to secrete histamine,
which then binds to the H2-receptors on the parietal cells and activates the H+/K+ATPase
proton pump to generate acid [11]. One ofthe most significant biologic characteristics of
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Figure 3. Human oxyntic mucosa showing
thenormal distributional pattern ofthe ECL
cells. Note that these cells are mostly present
in the lower and middle-third of the mucosal ~ Z;w thickness and are randomly dispersed in the
glandularlining. Lateral cytoplasmic processes
9! i tW ofsomeECLcellscanbeseenextendingtowards
'SA~ s b theadjacentparietal cells (SevierMunger stain).
the ECL cells is their exquisite sensitivity to the secretagogue and trophic influence of
gastrin. Acute hypergastrinemia causes histamine release from the ECLcells and enhances
the synthesis of histidine decarboxylase, which catalyses the formation of histamine from
histidine [12, 13]; while chronic hypergastrinemic states, on the other hand, induce an
ECL cell hyperplasia that can in some cases progress to neoplasia (ECL cell carcinoids)
[13-30].Although the precise mechanism by which gastrin stimulates ECL cell proliferation
1 Figure 4. Photomicrograph
. ~~~~oftheultrastructural charac- Xg. teristics of a human ECL
cell. Note the characteristic
large sized vacuolated type of
neurosecretory granules with
an eccentric electron dense
W7 core and wideperipheral halo. Ahe ECLcellsistheir exquisite senitiitytoheecrta (Courtesy of Dr. Herbert
Helander).
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remains unclear, it has been suggested that this too is perhaps mediated through histamine
release from the ECL cells since in addition to being a potent neurotransmitter, histamine
can also act as a mitogen [31].
Despite the fact that they are the dominant endocrine cell type in the oxyntic gastric
mucosa in all vertebrate species studied so far, the ECL cells remained largely ignored
until recently, and whereas knowledge related to the pathobiology ofother gastrointestinal
endocrine cells advanced rapidly, thatrelated to the ECLcells lagged woefully behind. All
this changed rapidly within the lastdecade or so when ECLcell hyperplasias and ECLcell
carcinoids were seen to develop in the glandular stomach ofrats after prolonged administra-
tion ofhigh doses ofantisecretory agents (e.g., cimetidine, ranitidine and omeprazole, etc.
[16, 17, 19, 32-36]). Aflurry ofinvestigative activity focusing on these cells subsequently
showed that both the hyperplastic and neoplastic ECL cell lesions were pathogenetically
related to the chronic hypergastrinemia induced by the prolonged suppression of acid
secretion in these animals [13, 16, 17, 19, 20, 22, 36].
Attention swiftly shifted towards human ECL cells to see if patients on long-term
antisecretory therapy might also be at risk for developing similar lesions. This represented
a very genuine and relevant concern, since these agents were being increasingly pre-
scribed not only for the long-term management of duodenal ulcer disease, gastroe-
sophageal reflux disease and theZollinger-Ellison syndrome buthave since then also been
recommended as adjuvants for eradicating Helicobacterpylori infection as well [37-41].
ECL CELL HYPERPLASIA
Hyperplasia signifies a non-autonomous proliferation ofa given cell type thatresults in
an increase in its total cell mass. It is amorphologic phenomenon that implies the presence
ofincreased numbers ofcells per unit area and requires morphologic criteria for its recogni-
tion and confirmation. Since the population density of a given endocrine cell type (e.g.,
the G, D, EC or ECL cell) in the gut not only shows considerable normal variation
between the different anatomic locations butis also influencedby age andgender [42, 43],
a diagnosis ofG, D, EC, or ECL cell hyperplasia relies primarily on the identification of
increased numbers (beyond twice the standard deviation in age-, gender- and site-matched
controls) ofcells perunit area ofmucosa [4, 44]. This, in the past, entailed alabor-intensive,
time-consuming morphometric quantitation of the cells to document an increase in
absolute cell numbers before a diagnosis ofhyperplasia could be established.
PROBLEMS RELATED TO THE STUDY OF ECL CELL HYPERPLASIA
One ofthe major problems in the study ofECLcell hyperplasias relates to the technical
limitations in our ability to specifically identify ECL cells at the light microscopic level in
routinely processed tissues. The histochemical techniques currently used for their visual-
ization lack specificity and provide only a rough approximation of their numbers. While
other endocrine cell types are easily identified immunohistochemically by antibodies
directed towards their secretory products, this methodology cannot be applied to ECL
cells since histamine is either leached out, destroyed or otherwise rendered nonimmunore-
active in formalin-fixed, paraffin embedded tissues. Thus, the special procedural modifi-
cations (freeze-drying, vapor-fixation and cryostat sectioning, etc.), so essential for their
specific immunohistochemical localization, have not only impaired our ability to visualize
ECL cells in routinely processed surgical pathology material, but have also precluded any
retrospective studies on archival material as well [5, 7]. Until quite recently, therefore, a
261Dayal: Classification ofECL cellproliferations
specific identification of ECL cells had traditionally depended on a combination of their
argyrophil and ultrastructural characteristics [45]. Secondly, ECL cell hyperplasias have
traditionally been difficult to recognize clinically because these cells release most oftheir
histamine locally into the tissues and do notrelease enough ofit into theblood to give rise
to a specific biochemical abnormality orclinical syndrome. In fact, the very entity ofECL
cell hyperplasia had remained suspect until recently when its association with chronic
hypergastrinemia was first recognized. Thirdly, even though we now know that such
hyperplasias are commonly associated with certain clinical conditions, they are hard to
detect since they do not produce any distinctive recognizable lesions that can be biopsied
endoscopically or sampled selectively in resected specimens. Histologically too, they can
be easily missed on routine hematoxylin and eosin stained specimens unless they are
specifically sought for by special argyrophil stains such as the Grimelius or Sevier-
Munger. Fourthly, incertainconditions (e.g., chronic atrophic gastritis andpernicious anemia),
commonly associated with such hyperplasias, the involved gastric mucosa is significantly
atrophied, and it is difficult to establish if the increased population density of ECL cells
represents agenuinehyperplasia or amereovercrowding ofinvoluting cells brought about
by mucosal atrophy and decreased mucosal volume, or a combination of the two.
Similarly, in conditions such as the Zollinger-Ellison syndrome, the presence ofincreased
numbers ofECL cells dispersed throughout the mucosal thickness may be masked by the
generalized oxyntic mucosal hypertrophy. Lastly, confusion related to documentation of
endocrine cell hyperplasia had also resulted from differences in the morphometric
methodologies and the frames of references employed by various workers. Thus, while
some workers counted individual cells, others used computerized point-counting tech-
niques, while yet others quantitated the hyperplastic population by measuring absorbance
of light and the fractional surface area of the tissue section in which such absorbance
occurred [46, 47]. Results, too, were expressed in such variable terms of reference as
absolute cell counts per square mmofmucosa, cells perunit length ofmucosa, highpower
field, gland or crypt and even in terms ofvolume density (proportion ofmucosal volume
occupied by endocrine cells) [23, 48, 49].
MECHANISMS OF ECL CELL HYPERPLASIA
Despite the sudden spurt in ourinterest in the pathobiology ofthese cells, we are still
unclear about the basic mechanisms responsible for ECL cell hyperplasia. Cumulative
evidence indicates that hyperplasias of ECL cells can theoretically result from a number
of different mechanisms such as prolongation oftheir half-life, differentiation of a larger
Table 2. Conditions associated with increased risk for ECL cell hyperplasia and multicentric
gastric carcinoids.
* Chronic atrophic gastritis (Type A)
* Pernicious anemia
* Zollinger-Ellison syndrome (familial and sporadic)
* Patients on pharmacologic gastric acid blockade
(H2 receptors; proton pump inhibitors)
* Chronic renal failure (+ hemodialysis)
* Autoimmune disorders:
- Polyglandular autoimmune syndrome
- Diabetes mellitus - Type 1 (insulin-dependent diabetes mellitus)
- Rheumatoid arthritis
- Sjogren's syndrome
- Addison's disease
- Myxedema
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Table 3. Classification ofECL cell proliferations.
* Hyperplasia:
- Simple (diffuse)
- Linear
- Micronodular
- Adenomatoid
* Dysplasia (pre-neoplastic stage):
- Enlarging micronodule
- Fusing micronodule
- Microinvasive lesion
- Nodule with newly formed stroma
* Carcinoid (neoplastic stage):
- Intramucosal carcinoid
- Invasive carcinoid
fraction ofpluripotent stem cells into ECL cells, enhanced self-replication offunctionally
mature ECLcells or even amodulation oftheir apoptotic destruction. Eachofthese mech-
anisms could be triggered by a release from the normal restraining influence of an
inhibitor of ECL cell proliferation, an interruption of the normal physiologic negative
feedback mechanism governing their status, or the trophic stimulation by a secretagogue
and/or regulatory substance (e.g., a peptide such as gastrin, or an amine such as serotonin
or histamine)[16, 17, 50-53]. More recently, with the recognition that ECL cells not only
secrete histamine but also have H3-receptors on their surface, an autocrine mechanism
whereby histamine liberated from the ECLcells can bind to these receptors and modulate
ECL cell proliferation has also been implicated [31]. Since these mechanisms are not
mutually exclusive, ECLcellhyperplasias canresultfromacombinationofthesemechanisms.
Furthermore, the local tissue and intraluminal microenvironment (e.g., gastric motility,
distension, H. pylori infection, mucosal atrophy, epithelial metaplasia with a consequent
rise in intraluminal pH and overexpression oftheirgastrin receptors, etc.) could, by influ-
encing any one or more of these triggering mechanisms, also play an important role not
only in the initiation and maintenance ofECL cell hyperplasias but also in their progres-
sion to ECL cell carcinoids [49, 54].
It must, however, be mentioned that although ECLcellhyperplasia caneitherbe apri-
mary event or be secondarily induced, only secondary hyperplasias ofthe ECLcells have
been described so far. Such hyperplasias are mostoften diagnosed because ofahigh index
ofclinical suspicion when such predisposing conditions as chronic atrophic gastritis, perni-
cious anemia, Zollinger-Ellison syndrome or chronic hypergastrinemia from other causes
are encountered (Table 2). While each ofthese conditions is known to have a strong asso-
ciation with ECL cell hyperplasia, these hyperplasias are now also being increasingly
observed in patients receiving long-term gastric acid suppressive therapy with H2-blockers
orproton pumpinhibitors [23, 55-60]. TheECLcellhyperplasia seeninthesepatients is also
due to the hypergastrinemia that is secondarily induced by these therapeutic agents [55,
59, 60]. In the oxyntic mucosa ofchronically hypergastrinemic patients (with gastrin levels
greater than three times normal), argyrophil stains show a morphologic spectrum of
hyperplastic lesions ranging from a diffuse increase in ECL cell numbers at one end,
through linear and nodular aggregates to frank ECL cell carcinoids [24, 25, 61, 62]. Such a
progression from diffuse hyperplasia through linear and micronodular hyperplasia to car-
cinoid tumors was formalized into a hyperplasia-neoplasia sequence by an international
committee headed by Enrico Solcia. The resultant classification, published in 1988, has,
therefore, come to be known as the "Solcia Classification" [4] and is reproduced inTable 3.
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Figure 5. Simple (Diffuse)
hyperplasia ofECLcellsinthe
oxyntic mucosa of a patient
with chronic atrophic gastri-
tis type A. Note that despite
the rather diffuse distribution-
al pattern of these cells
throughout the mucosal thick-
ness, some preferential clus-
tering is present in the lower
third. The argyrophil ECL
cells are hypertrophied and
dispersed singly or in small
clusters of three or four cells
in the closely packed glands
(Sevier-Munger stain).
Figure 6. Linearhyperplasia
of ECL cells in the oxyntic
mucosa of a patient with
severe chronic atrophic gas-
tritis typeA. Note the mucosal
atrophy, architectural distor-
tion and the markedly increased
numbers ofECLcells arranged
in a linear fashion along the
basement membrane of the
gastric glands. A couple of
small compact micronodular
aggregates ofpositively stained
endocrine cells are also pre-
sent. (Chromogranin stain with
hematoxylin counterstain).
Figure 7. Oxyntic mucosaofa
patient with pernicious ane-
mia showing marked chronic
atrophic gastritis and endo-
crinecell micronodularhyper-
plasia. Note the mucosal atro-
phy, architectural distortion and
the micronodular clusters of
endocrine (ECL) cells deep in
the mucosa abutting the mus-
cularis mucosae. These clusters
ranging up to 100 pm in size
approximate the diameter of
the normal oxyntic glands.
(Hematoxylin and eosin stain).
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In this scheme, the earliest stage, calledsimpleordiffuse hyperplasia, is characterized
by a diffuse increase in ECLcell numbers as visualized by the Grimelius orSevier-Munger
stain. The cells are scattered diffusely throughout the mucosal thickness either singly or
in clusters ofup to three orfour cells per gland. The positively-stained argyrophil cells are
somewhat hypertrophied, and although they are diffusely distributed throughout the
mucosal thickness, are somewhat more numerous and prominent in the lower third. When
quantitated morphometrically, the number ofpositively-stained cells per unit area exceeds
2 standard deviations over the normal range in age- and gender-matched controls, and
stand out in sharp contrast to the normal (Figure 5). When the hyperplasia is more severe,
the endocrine cells are seen arranged in a linear, semilunar or a daisy-chain-like configu-
ration along the basement membrane ofthe gland and this stage is, therefore, designated
as linear hyperplasia (Figure 6). These linearchains are most often seen in the lower one-
third of the mucosal thickness and involve the basal portion of the glands that abut the
muscularis mucosae. They may, however, occasionally also be seen superficially in the
region of the glandular necks. These locations tend to reflect the different modes oftheir
histogenesis. Thus, while thehyperplastic ECLcells deep within the mucosa arepresumably
derived either from replication or longevity offunctionally mature ECLcells, modulation
of their apoptotic demise or autocrine mechanisms, those in the superficial mucus-neck
cell region (the proliferative compartment of the gastric mucosa) [14] are believed to
result from a preferential differentiation of the stem cells along an ECL cell phenotype.
Because these linear lesions are most often deep within the mucosa and may be focal or
diffuse, they frequently require multiple, full-thickness mucosal biopsies fortheir detection.
A diagnosis of linear hyperplasia requires a minimum of five chains of five contiguous
ECL cells each in one specimen or a minimum oftwo such chains per linear millimeter of
mucosa in multiple biopsies. This arrangement of argyrophil cells signifies a definite
hyperplasia since ECL cells do not normally show this morphologic arrangement.
However, the numerical stipulation given above is important since it distinguishes genuine
linear hyperplasias from the randomly scattered, discontinuous linear arrangements of
three to four argyrophil cells occasionally seen in mild cases of chronic atrophic gastritis.
The next recognizable stage in the sequence is characterized by the presence of solid
micronodular ECL cell clusters and is designated as micronodular hyperplasia. These
clusters, made up of five argyrophil cells or more, measure 100 to 150 gm in size and do
not exceed the diameter of a gastric gland. Micronodular ECL cell hyperplasia is the earliest
stage that can be visualized with the hematoxylin and eosin stain (Figure 7) and has been
variously referred to as argyrophil cell clusters, argyrophil cell micronodules, argyrophil
cell nests, endocrine cell micronests and microcarcinoids by other workers [63-65]. For a
diagnosis ofmicronodular ECL cell hyperplasia a minimum of one such nodule per linear
millimeter of mucosa should ideally be present in a background of simple and/or linear
hyperplasia. Although such micronodularclusters, bounded by an intact basement membrane
contiguous with that ofthe rest ofthe gland, are characteristically located in the basiglandular
portion of the mucosa, similar but smaller nodules may be seen dissociated from the
glands and lying free in the lamina propria abutting the muscularis mucosae (Figure 8).
While such a dissociation could in some cases be due to tangential sectioning, tortuousity
of the gland or the micronodule itself, or even a budding of the micronodule from the
gland, such nodules actually represent aggregates of residual endocrine cells left behind
after the glands have atrophied and disappeared. Such dissociated aggregates are, there-
fore, called micronodular pseudohyperplasia. In contrast to the 100-150 ,um sized nodules
of genuine ECL cell hyperplasia that occur in a background of simple- and linear hyper-
plasia, the pseudohyperplastic nodules are much smaller in diameter (< 50 gm), and are
neither associated with any increase in absolute ECL cell numbers, nor with any simple
or linear hyperplasia. Furthermore, the pseudohyperplastic nodules have a heterogeneous
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Figure8.Oxynticmucosaofthesamepatientshow-
ing several micronodular clusters of endocrine
(ECL) cells dispersed in the mucosa in a back-
ground oflinearhyperplasia. Most ofthe clusters
have between 20-25 positively stained cells in them.
The smallest clusters represent pseudohyperplastic
micronodules of endocrine cells, from atrophied
glands (chromogranin stain).
Figure9.Adenomatoidhyper-
plasiaofECLcellsintheoxyn-
tic mucosa of a patient with
chronic atrophic gastritis type
A.Notethecompact"adenoma-
4.^l lIike"clustering ofseveral micro-
nodules, each with its base-
~ tment membrane still intact
$ > ^ (Grimelius stain with methyl
W, green counterstain).
MX Figure 10. Dysplastic lesion
showing alarge clusterofen-
docrine(ECL)cellsdeepwith-
in the oxyntic mucosa of a
patient with chronicatrophic
gastritis type A. Note that the
clusterslackanidentifiablebase-
ment membrane, and that the
:: ::: : dysplastic cells infiltrate both
the laminapropriabetweenthe
t1*;wd glands and the muscularis
mucosae. (Chromogranin stain).
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cellular composition and, often contain some non-argyrophil and chromogranin-immuno-
negative residual epithelial cells trapped within them. Ultrastructurally too, the endocrine
cells in such clusters contain increased numbers ofintracytoplasmic lipid droplets, swollen
mitochondria, excessively dilated endoplasmic reticulum, a dense cytoplasmic matrix,
decreased numbers of small, dense, non-diagnostic neurosecretory granules and pyknotic
nuclei, all ofwhich are features ofcytologic involution rather than stimulatory activation.
Hyperplastic ECL cells, on the other hand, show such features of active protein synthesis
as abundant rough endoplasmic reticulum and a prominent Golgi apparatus. Interestingly,
however, these hyperplastic cells show a marked reduction in the number of vacuolated/
vesicular granules (which are the hallmark ofresting ECL cells) and a marked increase in
the coarsely textured granules.Additionally, apunctate type ofneurosecretory granule has
also been occasionally observed in hyperplastic ECL cells [66]. It should, however, be
pointed out that not only do these two types of micronodular lesions frequently co-exist
in the gastric mucosa of hypergastrinemic patients with CAG-A and pernicious anemia,
but that the pseudohyperplastic clusters often occur alone (and without coexistent simple
and linear hyperplasia) in such diverse conditions as H. pylori infection, gastric ulcer and
gastric cancer, etc., that show significant gastritis. Thus, because of their heterogeneous
composition and their involutional character, such extraglandular clusters are clearly dif-
ferent from the monotypic hyperplastic ECLcell micronodules and need to be differentiated
from them because they are not influenced by hypergastrinemia and do not have any signif-
icant proliferative potential. Such a differentiation is chiefly based on a combination of
their small size (50 ,um vs. 150 gm), cytological heterogeneity and their presence exclu-
sively in areas of gland atrophy. Because ECL cell hyperplasias occur diffusely in the
oxyntic mucosa, the Solciaclassification insists onfinding aminimumofone 10 to 150jm-
sized micronodule per linear millimeter ofmucosa with or without abackground ofsimple
and/or linear hyperplasia.
Continued growth of the intraglandular pure ECL cell micronodules, each with its
intact basement membrane, on the other hand, leads to the formation of small aggregates
ofseveral micronodules closely packed together in aback-to-back arrangement. Because of
this adenoma-like arrangement ofmicronodules, this stage is referred to as adenomatoid
hyperplasia (Figure 9). This lesion has been regarded as a focal exaggeration of micron-
odular hyperplasia and is, therefore, closely similar to it both in morphology and biological
behavior. It is, however, important to distinguish it from the dysplastic (precarcinoid)
lesions that are characterized by an enlargement of adenomatoid micronodules, break-
down ofthe basement membrane surrounding each individual micronodule in the cluster,
presence of cytologic atypia, increased nuclear-cytoplasmic ratio and a reduction in the
intensity of argyrophilia. Dysplastic lesions, thus, appear as nodular or irregular 150 gm
to 0.5 mm sized clusters of argyrophil cells infiltrating the lamina propria (Figure 10).
These lesions show a number ofmorphologic variations that are designated as enlarging
micronodules (nodular aggregates more than 150 gm in diameter),fusing micronodules
(from fusion ofseveral adjacent micronodules), microinvasive lesions (clusters ofatypical
cells infiltrating the lamina propria between the glands) and nodules with newlyformed
stroma (when the nodules acquire a lobular or trabecular pattern).
Since dysplastic lesions too are multifocal in distribution, any one or more of these
variant subtypes may be encountered in a biopsy specimen(s) at any time.
Following the publication ofthe Solcia classification, several studies have conclusively
shown that whereas the simple, linear, micronodular and adenomatoid types of ECL cell
hyperplasias have a low or negligible potential for carcinoidogenesis, the dysplastic
lesions have a strong association either with thepresence ofco-existentECLcellcarcinoid(s)
or of an increased risk ofdeveloping them in the future [67]. Conceptually, therefore, the
dysplastic stage marks the borderline between the clearly hyperplastic stages preceding it
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Figure lla (top). Oxyntic mu-
Cosa of a patient with chronic
atrophic gastritis type A and
multiple gastric carcinoids.
The tumor shows invasion into
the underlying submucosa.
Figure llb (bottom). Grime-
p. .s 1)~ = ~ lius stainofthetumorshowing
~~~ ~~~ ~argyrophilia ofthe tumor cells
and prominent foci of linear
-N~~ ~ *~#~.- and micronodular ECL cell
~~ ~~ .~~ hyperplasia in the adjacent ~~ ~~ ~~ non-tumorous mucosa.
and the neoplastic (carcinoid) stage following it in sequence and represents the first
"point-of-no-return" in the hyperplasia-neoplasia sequence of ECL cell proliferations.
Because dysplastic lesions are less than 0.5 mnm in size, they are not visible endoscopically,
and are invariably first detected during microscopy. In clinical terms, since the detection
of a dysplastic ECL cell lesion in a gastric biopsy indicates the presence of a coexistent
carcinoid(s) or asignificantriskofdeveloping them, it shouldprompt acarefulre-endoscopy
with extensive sampling ofthe oxyntic mucosa for any ECL cell carcinoid that may have
been missed. The carcinoid stage in this scheme, is characterized by nodular infiltrating
growths greater than 0.5 mm in diameter (Figure II). These lesions are completely intra-
mucosal at first, but gradually extendintramurally, and may even invade vascular orlym-
phatic channels to produce nodal and distant metastases.
Because the Solcia classification is based on a combination ofquantitative andmorpho-
logical criteria with emphasis on the morphologic pattern ofECL cell hyperplasia, it rep-
resents a significant improvement over the labor-intensive, time-consuming morphometric
methods that were used before. Based on a visualization of ECL cells by a commonly
employed argyrophil stain (Grimelius), this classification clearly identifies the various
stages in thehyperplasia-neoplasia sequence ofECLcellproliferation andclearly defines the
morphologic criteria for each. The classification is easy to use and has a high degree of
inter-observerreproducibility. Theascending grades ofhyperplasia in this scheme correlate
well withmorphologic results [44]. The Solciaclassificationhas, therefore, achieved ahigh
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degree of acceptance amongst practicing pathologists. By calling attention to the biologic
characteristics of the various stages of ECL cell hyperplasia and the pseudohyperplastic
nodules, the Solcia classification has not only rationalized the current recommendations
for antrectomy as treatment in select cases of ECL cell carcinoids, but has also helped
explain why antrectomy sometimes results in regression ofonly some but not all micron-
odular lesions [68-71]. Furthermore, by establishing both the histologic criteria and the
precursor lesions associated with ECLcell carcinoids, the Solcia classification has helped
separate the relative benign, slow-growing, gastrin-dependent ECL cell carcinoids that
require a conservative therapeutic approach from the more aggressive spontaneously
occurring gastric carcinoids where a more radical surgical approach needs to be adopted.
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